MDWD vs NVCR vs HOLX vs SYK

For growth investors, Stryker Corporation (SYK) is the stronger pick with 11.

2% revenue growth year-over-year, versus -16. 1% for MediWound Ltd. (MDWD). Hologic, Inc. (HOLX) offers the better valuation at 30. 5x trailing P/E (17. 2x forward), making it the more compelling value choice. Analysts rate MediWound Ltd. (MDWD) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Hologic, Inc.

(HOLX) is the cheapest at 30. 5x versus Stryker Corporation at 35. 0x. On forward P/E, Hologic, Inc. is actually cheaper at 17. 2x.

Over the past 5 years, Stryker Corporation (SYK) delivered a total return of +21.

5%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: SYK returned +179. 2% versus MDWD's -69. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Hologic, Inc.

(HOLX) is the lower-risk stock at 0. 45β versus NovoCure Limited's 2. 15β — meaning NVCR is approximately 373% more volatile than HOLX relative to the S&P 500. On balance sheet safety, MediWound Ltd. (MDWD) carries a lower debt/equity ratio of 20% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Stryker Corporation (SYK) is pulling ahead at 11.

2% versus -16. 1% for MediWound Ltd. (MDWD). On earnings-per-share growth, the picture is similar: MediWound Ltd. grew EPS 30. 7% year-over-year, compared to -25. 0% for Hologic, Inc.. Over a 3-year CAGR, SYK leads at 10. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Hologic, Inc.

(HOLX) is the more profitable company, earning 13. 8% net margin versus -140. 8% for MediWound Ltd. — meaning it keeps 13. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SYK leads at 19. 5% versus -149. 1% for MDWD. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Hologic, Inc.

(HOLX) trades at 17. 2x forward P/E versus 19. 1x for Stryker Corporation — 1. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MDWD: 108. 5% to $36. 00.

In this comparison, SYK (1.

1% yield) pays a dividend. MDWD, NVCR, HOLX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

52), 1. 1% yield, +179. 2% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 15 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SYK: +179. 2%, NVCR: +38. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

SYK pays a dividend while MDWD, NVCR, HOLX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.